Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2020, Vol. 11 Issue (4) : 725-729     DOI: 10.14336/AD.2020.0629
Editorial |
Geroscience in the Age of COVID-19
Nir Barzilai1,*, James C Appleby2, Steven N Austad3, Ana Maria Cuervo1, Matt Kaeberlein4, Christian Gonzalez-Billault5,6, Stephanie Lederman7, Ilia Stambler8,*, Felipe Sierra9,*
1Institute for Aging Research, Albert Einstein College of Medicine, New York, NY, USA
2Gerontological Society of America, USA
3Department of Biology, University of Alabama at Birmingham, USA
4Department of Pathology, University of Washington, USA
5Geroscience Center for Brain Health and Metabolism (GERO), Chile
6The Buck Institute for Research on Aging, USA
7American Federation for Aging Research, USA
8Vetek (Seniority) Association - the Movement for Longevity and Quality of Life, Israel
9National Institute on Aging, NIH, USA
Download: PDF(222 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

The data on COVID-19 is clear on at least one point: Older adults are most vulnerable to hospitalization, disability and death following infection with the novel coronavirus. Therefore, therapeutically addressing degenerative aging processes as the main risk factors appears promising for tackling the present crisis and is expected to be relevant when tackling future infections, epidemics and pandemics. Therefore, utilizing a geroscience approach, targeting aging processes to prevent multimorbidity, via initiating broad clinical trials of potential geroprotective therapies, is recommended.

Keywords geroscience      COVID-19      immunosenescence      geroprotectors      aging biomarkers     
Corresponding Authors: Barzilai Nir,Stambler Ilia,Sierra Felipe   
About author: These authors contributed equally to this work.
Just Accepted Date: 06 July 2020   Issue Date: 01 August 2020
E-mail this article
E-mail Alert
Articles by authors
Barzilai Nir
James C Appleby
Austad Steven N
Cuervo Ana Maria
Kaeberlein Matt
Gonzalez-Billault Christian
Lederman Stephanie
Stambler Ilia
Sierra Felipe
Cite this article:   
Barzilai Nir,James C Appleby,Austad Steven N, et al. Geroscience in the Age of COVID-19[J]. Aging and disease, 2020, 11(4): 725-729.
URL:     OR
[1] Wu Z, McGoogan JM (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 323(13):1239-1242.
[2] Miller RA (2002). Extending life: scientific prospects and political obstacles. Milbank Q, 80:155-174.
[3] Sierra F, Kohanski P (2017). Geroscience and the trans-NIH Geroscience Interest Group, GSIG. Geroscience, 39(1):1-5.
[4] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013). The hallmarks of aging. Cell, 153(6):1194-1217.
[5] Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. (2014). Geroscience: linking aging to chronic disease. Cell, 159:709-713.
[6] Longo VD, Antebi A, Bartke A, Barzilai N, Brown-Borg HM, Caruso C, et al. (2015). Interventions to slow aging in humans: are we ready? Aging Cell, 14(4):497-510.
[7] Kaeberlein M, Rabinovitch PS, Martin GM (2015). Healthy aging: the ultimate preventative medicine. Science, 350(6265):1191-1193.
[8] Aw D, Silva AB, Palmer DB (2007). Immunosenescence: emerging challenges for an ageing population. Immunology, 120(4):435-446.
[9] Kulkarni AS, Gubbi S, Barzilai N (2020). Benefits of metformin in attenuating the hallmarks of aging. Cell Metab, in press.
[10] Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA (2016). Metformin as a tool to target aging. Cell Metab, 23:1060-1065.
[11] Bailey CJ (2017). Metformin: historical overview. Diabetologia, 60(9):1566-1576.
[12] Diaz A, Romero M, Vazquez T, Lechner S, Blomberg BB, Frasca D (2017). Metformin improves in vivo and in vitro B cell function in individuals with obesity and Type-2 Diabetes. Vaccine, 35(20):2694-2700.
[13] Luo P, Qiu L, Liu Y, Liu XL, Zheng JL, Xue HY, et al. (2020). Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg, in press.
[14] Bramante C, Ingraham N, Murray T, Marmor S, Hoversten S, Gronski J, et al. (2020). Observational study of metformin and risk of mortality in patients hospitalized with Covid-19. MedRxiv, in press.
[15] Chen C, Liu Y, Liu Y, Zheng P (2009). mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal, 2(98):ra75.
[16] Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. (2014). mTOR inhibition improves immune function in the elderly. Sci Transl Med, 6:268ra179.
[17] Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med, 10:eaaq1564.
[18] Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, et al. (2018). A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects. Exp Gerontol, 105:53-69.
[19] Blagosklonny MV (2019). Rapamycin for longevity: opinion article. Aging (Albany NY), 11:8048-8067.
[20] Moskalev A, Stambler I, Caruso C (2020). Innate and adaptive immunity in aging and longevity: the foundation of resilience. Aging Dis, in press.
[21] Belsky DW, Caspi A, Houts R, Cohen HJ, Corcoran DL, Danese A, et al. (2015). Quantification of biological aging in young adults. Proc Natl Acad Sci USA, 112(30):E4104-4110.
[22] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. (2020). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis, 94:91-95.
[23] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the Northwell COVID-19 Research Consortium. (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA, 323(20):2052-2059.
[24] Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD (2020). Renin-Angiotensin-Aldosterone system inhibitors in patients with Covid-19. New Engl J Med, 382(17):1653-1659.
[25] Newman JC, Milman S, Hashmi SK, Austad SN, Kirkland JL, Halter JB, Barzilai N (2016). Strategies and challenges in clinical trials targeting human aging. J Gerontol A Biol Sci Med Sci, 71:1424-1434.
[26] Stambler I (2017). Recognizing degenerative aging as a treatable medical condition: methodology and policy. Aging Dis, 8(5):583-589.
[27] Ferrucci L, Gonzalez-Freire M, Fabbri E, Simonsick E, Tanaka T, Moore Z, et al. (2020). Measuring biological aging in humans: a quest. Aging Cell, 19(2):e13080.
[28] Jin K, Simpkins JW, Ji X, Leis M, Stambler I (2015). The critical need to promote research of aging and aging-related diseases to improve health and longevity of the elderly population. Aging Dis, 6(1):1-5.
[29] Stambler I, Jin K, Lederman S, Barzilai N, Olshansky SJ, Omokaro E, et al. (2018). Aging health and R&D for healthy longevity must be included into the WHO Work Program. Aging Dis, 9(2):331-333.
[1] Undurti N Das. Bioactive Lipids as Mediators of the Beneficial Action(s) of Mesenchymal Stem Cells in COVID-19[J]. Aging and disease, 2020, 11(4): 746-755.
[2] Ting Wu,Zhihong Zuo,Shuntong Kang,Liping Jiang,Xuan Luo,Zanxian Xia,Jing Liu,Xiaojuan Xiao,Mao Ye,Meichun Deng. Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis[J]. Aging and disease, 2020, 11(4): 874-894.
[3] Pedro C Lara,David Macías-Verde,Javier Burgos-Burgos. Age-induced NLRP3 Inflammasome Over-activation Increases Lethality of SARS-CoV-2 Pneumonia in Elderly Patients[J]. Aging and disease, 2020, 11(4): 756-762.
[4] Michael D Schwartz,Stephen G Emerson,Jennifer Punt,Willow D Goff. Decreased Naïve T-cell Production Leading to Cytokine Storm as Cause of Increased COVID-19 Severity with Comorbidities[J]. Aging and disease, 2020, 11(4): 742-745.
[5] Feng He,Yibo Quan,Ming Lei,Riguang Liu,Shuguang Qin,Jun Zeng,Zhao Ziwen,Na Yu,Liuping Yang,Jie Cao. Clinical features and risk factors for ICU admission in COVID-19 patients with cardiovascular diseases[J]. Aging and disease, 2020, 11(4): 763-769.
[6] Agnieszka Neumann-Podczaska,Salwan R Al-Saad,Lukasz M Karbowski,Michal Chojnicki,Slawomir Tobis,Katarzyna Wieczorowska-Tobis. COVID 19 - Clinical Picture in the Elderly Population: A Qualitative Systematic Review[J]. Aging and disease, 2020, 11(4): 988-1008.
[7] Xiaotian Dong, Mengyan Wang, Shuangchun Liu, Jiaqi Zhu, Yanping Xu, Hongcui Cao, Lanjuan Li. Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)[J]. Aging and disease, 2020, 11(3): 642-648.
[8] Sankha Shubhra Chakrabarti, Upinder Kaur, Anindita Banerjee, Upasana Ganguly, Tuhina Banerjee, Sarama Saha, Gaurav Parashar, Suvarna Prasad, Suddhachitta Chakrabarti, Amit Mittal, Bimal Kumar Agrawal, Ravindra Kumar Rawal, Robert Chunhua Zhao, Indrajeet Singh Gambhir, Rahul Khanna, Ashok K Shetty, Kunlin Jin, Sasanka Chakrabarti. COVID-19 in India: Are Biological and Environmental Factors Helping to Stem the Incidence and Severity?[J]. Aging and disease, 2020, 11(3): 480-488.
[9] Selçuk Öztürk, Ayşe Eser Elçin, Yaşar Murat Elçin. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?[J]. Aging and disease, 2020, 11(3): 477-479.
[10] Pietro Gentile, Aris Sterodimas. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease[J]. Aging and disease, 2020, 11(3): 465-469.
[11] Hong Liu, Shiyan Chen, Min Liu, Hao Nie, Hongyun Lu. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis[J]. Aging and disease, 2020, 11(3): 668-678.
[12] Zikuan Leng, Rongjia Zhu, Wei Hou, Yingmei Feng, Yanlei Yang, Qin Han, Guangliang Shan, Fanyan Meng, Dongshu Du, Shihua Wang, Junfen Fan, Wenjing Wang, Luchan Deng, Hongbo Shi, Hongjun Li, Zhongjie Hu, Fengchun Zhang, Jinming Gao, Hongjian Liu, Xiaoxia Li, Yangyang Zhao, Kan Yin, Xijing He, Zhengchao Gao, Yibin Wang, Bo Yang, Ronghua Jin, Ilia Stambler, Lee Wei Lim, Huanxing Su, Alexey Moskalev, Antonio Cano, Sasanka Chakrabarti, Kyung-Jin Min, Georgina Ellison-Hughes, Calogero Caruso, Kunlin Jin, Robert Chunhua Zhao. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and disease, 2020, 11(2): 216-228.
[13] Brandenberger Christina, Kling Katharina Maria, Vital Marius, Christian Mühlfeld. The Role of Pulmonary and Systemic Immunosenescence in Acute Lung Injury[J]. Aging and disease, 2018, 9(4): 553-565.
[14] Lu Jiao, Duan Xuefeng, Zhao Wenming, Wang Jing, Wang Haoyu, Zhou Kai, Fang Min. Aged Mice are More Resistant to Influenza Virus Infection due to Reduced Inflammation and Lung Pathology[J]. Aging and disease, 2018, 9(3): 358-373.
[15] Zinger Adar, Cho William C, Ben-Yehuda Arie. Cancer and Aging - the Inflammatory Connection[J]. Aging and disease, 2017, 8(5): 611-627.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd